Clarivate sells Life Sciences & Healthcare business to Altaris for $600M

CLARIVATE PLC

Purchase price $600M: $500M cash at close, $25M deferred, $75M senior note.
Transaction expected to close by end of 2026; no shareholder vote required.
Buyer's termination fee of $33M guaranteed by Altaris funds.
Henry Levy, President of the business, gets retention agreement: RSU vesting, PSU cancellation, severance if terminated without cause within 6 months post-close.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.